ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 666

Leukadherin 1, a CR3 Mimetic, Negatively Regulates Toll Like Receptor (TLR) Dependent Inflammatory Responses via  Degradation of an Adaptor Protein

Kristen Lee1, Joanne H. Reed2, Vineet Gupta3, Tejaskumar Patel2, Jill P. Buyon4 and Robert M. Clancy2, 1Rheumatology, NYU Langone Medical Center, New York, NY, 2Medicine, New York University School of Medicine, New York, NY, 3Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miami, FL 33136, U.S.A., Miami, FL, 4Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: immune response, Integrins, macrophages, signal transduction and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Systemic Lupus Erythematosus is characterized by continuous and cyclic stimulation of the innate immune system by endogenous nucleic acids. Immune complexes of Ro60, ssRNA and anti-Ro60 have been shown to engage TLR7 and promote secretion of inflammatory mediators.  Recent evidence demonstrates that activation of the integrin, CR3, negatively regulates TLR signaling in dendritic cells. Leukoadhedrin (LA1), a novel small molecule, allosterically activates CR3 and suppresses inflammation.  This study was initiated to molecularly address whether, and by what mechanism, LA1 downregulates ssRNA-induced TLR7 signaling in macrophages. 

Methods: THP-1 cells and PBMC derived CD14+ macrophages from healthy human donors were incubated with TLR7/8 agonists (hY3 (2.5 ug) or R848 (1 uM)) with and without LA1 (7.5μM) added 30 minutes pre or post stimulation. Quantification of TNFα secretion, the readout of TLR7/8 activation, was assessed by ELISA and MyD88 was evaluated by immunoblot.

Results: Exposure of healthy human macrophages to hY3 resulted in a significant release of TNFα compared to unstimulated cells (348±45 vs 4±2 pg/ml, respectively P=0.0001, N=9).   Stimulated TNFα release was markedly decreased by pre-treatment with LA1 but not post-treatment (53±47 and 1275±467 pg/ml, respectively, P=0.035, N=6).  In parallel with the results for isolated macrophages, TNFα was induced after exposure of THP-1 macrophages to hY3 (315±59 vs 15±13 pg/ml, stimulated vs. unstimulated respectively P=0.0015, N=7).   Pre-treatment with LA1 profoundly decreased hY3-induced secretion (18±9 pg/ml, P=0.0013 vs hY3) and exceeded the inhibition observed with a TLR7 inhibitor (117±16 pg/ml, P=0.004 vs hY3).  Moreover, R848 stimulated TNFα release was also significantly decreased by pre-treatment with LA1 (1113±218 vs 55±47 pg/ml, respectively P=0.0006, N=11). To identify the potential mechanism for downregulation of TLR7 signaling, adaptor protein degradation was studied.  LA1-mediated inhibition of both hY3 and R848 stimulated TNFα release was accompanied by degradation of MyD88 (immunoblot, N=3 for each stimuli), an effect not seen with a TLR7 antagonist, oligonucleotide  IRS661 (inhibits at level of TLR ligation, not downstream).  Reprobe of blot demonstrated that the expression of actin did not vary with treatment condition.  Evidence against cytotoxcity of LA1 was provided by the absence of LDH in culture supernatants. The ITGAMassignment of THP-1 cells and all the donor macrophages was homozygous common at rs1143679 supporting that the inhibitory effect of LA1 was applicable to the dominant genotype. 

Conclusion: The data suggest that activation of CR3 downregulates macrophage TLR7 signalling via degradation of MyD88.  These findings may be particularly relevant in disease states such as SLE and neonatal lupus in which inflammatory cells are triggered by ssRNA containing immune complexes.


Disclosure:

K. Lee,
None;

J. H. Reed,
None;

V. Gupta,
None;

T. Patel,
None;

J. P. Buyon,

NIH 5R37AR042455,

2;

R. M. Clancy,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/leukadherin-1-a-cr3-mimetic-negatively-regulates-toll-like-receptor-tlr-dependent-inflammatory-responses-via-degradation-of-an-adaptor-protein/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology